SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 69 filers reported holding SYROS PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $127,000 | -56.9% | 106,700 | +17.8% | 0.00% | -100.0% |
Q4 2021 | $295,000 | -61.8% | 90,600 | -47.5% | 0.00% | -50.0% |
Q3 2021 | $772,000 | -44.7% | 172,700 | -32.6% | 0.00% | -50.0% |
Q2 2021 | $1,396,000 | -36.9% | 256,100 | -13.4% | 0.00% | -33.3% |
Q1 2021 | $2,213,000 | -11.6% | 295,800 | +28.2% | 0.01% | -14.3% |
Q4 2020 | $2,504,000 | +55.5% | 230,800 | +26.7% | 0.01% | +40.0% |
Q3 2020 | $1,610,000 | -17.1% | 182,100 | -0.1% | 0.01% | -16.7% |
Q2 2020 | $1,943,000 | +307.3% | 182,300 | +126.7% | 0.01% | +200.0% |
Q1 2020 | $477,000 | -34.6% | 80,400 | -23.8% | 0.00% | 0.0% |
Q4 2019 | $729,000 | +107.1% | 105,500 | +177.6% | 0.00% | +100.0% |
Q2 2019 | $352,000 | -6.1% | 38,000 | -7.3% | 0.00% | 0.0% |
Q1 2019 | $375,000 | +32.5% | 41,000 | -19.3% | 0.00% | 0.0% |
Q4 2018 | $283,000 | -57.1% | 50,800 | -8.3% | 0.00% | -50.0% |
Q3 2018 | $660,000 | -12.7% | 55,400 | -25.1% | 0.00% | 0.0% |
Q2 2018 | $756,000 | +620.0% | 74,000 | +585.2% | 0.00% | – |
Q4 2017 | $105,000 | – | 10,800 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Samsara BioCapital, LLC | 1,726,603 | $15,228,000 | 10.06% |
Flagship Pioneering Inc. | 3,204,437 | $29,673,000 | 1.28% |
Redmile Group, LLC | 3,620,376 | $33,525,000 | 0.95% |
ARK Investment Management | 3,791,756 | $35,112,000 | 0.88% |
Nikko Asset Management Americas, Inc. | 2,987,763 | $27,667,000 | 0.54% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,268,946 | $11,750,000 | 0.42% |
683 Capital Management, LLC | 429,775 | $3,980,000 | 0.36% |
EcoR1 Capital, LLC | 248,480 | $2,301,000 | 0.23% |
ALGERT GLOBAL LLC | 17,920 | $166,000 | 0.06% |
Baker Brothers Advisors | 974,835 | $9,027,000 | 0.06% |